• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Newsmakers: Darren Shirley

    Are You Prepared for the 2023 DSCSA Deadline?

    Rethinking the Changing Role of the CRO

    23rd Annual Salary Survey

    Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Phastar Appoints Chris Schoonmaker as Chief Operations Officer

    Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK

    EQT Private Equity Acquires SPT Labtech from Battery Ventures

    Shimadzu Scientific Instruments Extends HQ Campus

    Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Shimadzu Scientific Instruments Extends HQ Campus

    Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills

    Batavia Enters Commercial Manufacturing Business

    CoreRx Expands Capabilities

    Pierre Fabre and Lonza Enter Manufacturing Agreement
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Tubular Glass Primary Packaging for Pharmaceutical, Biotech and Diagnostic Containment

    How to Improve the Cold Chain System in Remote Locations

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Yourway to Build New Flagship European Depot

    Newsmakers: Darren Shirley
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK

    EQT Private Equity Acquires SPT Labtech from Battery Ventures

    Ixaka & Minaris Sign Tech Transfer & GMP Manufacturing Agreement for Cell Therapy Candidate

    MasterControl and Elemental Machines Form Biomanufacturing Partnership

    Charles River and Ziphius Vaccines to Manufacture saRNA-based Vaccine
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Should Remote Pharma GMP Audits End After COVID?

    Why is Big Pharma Increasingly Adopting 505(b)(2)?

    Sentry Biopharma Services: Protecting Pharmaceutical Integrity

    Selkirk Pharma Appoints New Head of Quality

    Be Safer by Doing Less: The Future of Zero Touch AE Case Processing
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Biosynth Carbosynth

    Societal CDMO

    Baxter BioPharma Solutions

    IDT Biologika

    Vector Partners Limited
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Biosynth Carbosynth

    Societal CDMO

    Baxter BioPharma Solutions

    IDT Biologika

    Vector Partners Limited
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    GlaxoSmithKline

    ...

    GlaxoSmithKline
    Related CONTENT
    • Syngene
    • Vetio Animal Health
    • Pricing Headwinds
    • Rawcliffe to Succeed Noble as Adaptimmune CEO
    • Pfizer, Inc.
    07.15.19
    Headquarters: Brentford, Middlesex, UK
    twitter.com/GSK
    www.gsk.com



    Headcount: 95,490 
    Year Established: 2000
    Revenues:  $40,992  (+1%)
    Pharma Revenues:  $30,807  (+2%)
    Net Income:  $5,381  (-2%)
    R&D:  $5,178   (-14%)

    TOP SELLING DRUGS  
    Drug Indication 2018 Sales (+/-%)
    Triumeq HIV $3,535 11%
    Seretide/Advair COPD $3,234 -20%
    Tivicay HIV $2,188 21%
    Breo Ellipta COPD $1,454 12%
    Hepatitis franchise Hepatitis A, B $1,079 21%
    Shingrix Shingles prophylaxis $1,047 n/a
    Ventolin asthma $984 0%
    Pediarix pediatric vaccine $908 -5%
    Lamictal anti-epileptic  $824 -2%
    Flovent respiratory $794 3%

    GlaxoSmithKline (GSK) reported revenue of $40.9 billion, up just 1% from the year before. The standout was Shingrix, GSK’s vaccine for shingles, which had sales of $1.0 billion in its launch year. HIV medicines also continued to grow with $3.5 billion in sales for Triumeq, GSK’s new top seller, and $2.2 billion for Tivicay.

    With the decline if its flagship product Advair, GSK continues to build its new respiratory portfolio with Trelegy Ellipta, the new three-in-one medicine for chronic obstructive pulmonary disease (COPD), and Nucala, GSK’s biologic medicine for severe asthma. In addition to the positive launches of Shingrix and Trelegy Ellipta, GSK reported a strong start to sales of HIV drug Juluca.

    During the year GSK implemented a new R&D approach to focus on science of the immune system, human genetics and advanced technologies. In fact, it made significant progress in reshaping its pharmaceuticals R&D portfolio to reflect this new strategy with 33 of 46 new medicines now targeting modulation of the immune system.

    As part of the its ongoing prioritization and strengthening of its pharmaceuticals pipeline, GSK transferred its portfolio of approved and investigational rare disease gene therapies to Orchard Therapeutics. GSK became an investor in Orchard as a result, receiving a 19.9% equity stake along with a seat on the company’s board. GSK and Orchard will exchange manufacturing, technical and commercial insights and learnings on the development of gene therapy medicines to ensure the success of the assets.

    In other business news, GSK entered a deal to create a consumer healthcare joint venture with Pfizer and bought out Novartis’ stake in GSK Consumer Healthcare. The combination of the iconic brands of GSK and Pfizer will create one of the largest consumer healthcare players in key geographies including the U.S., Europe, China, India and Australasia. Pfizer will contribute its consumer healthcare business to GlaxoSmithKline’s existing consumer healthcare business. The 2017 global sales for the combined business were approximately $12.7 billion. Pfizer receives a 32% equity stake in the joint venture.

    The joint venture will be a category leader in pain relief, respiratory, vitamin and mineral supplements, digestive health, skin health and therapeutic oral health.

    Following the integration, GSK said it intends to separate the joint venture as an independent company. GSK may also sell all or part of its stake in the joint venture in a contemporaneous IPO.

    Pumped up pipeline
    GSK strengthened its pipeline through business development initiatives with 23andMe and Tesaro. First, bolstering its cancer assets, GSK added the ovarian cancer drug Zejula to its portfolio when it paid $5.1 billion for Tesaro. The deal significantly strengthens GSK’s pharmaceutical business, accelerating the build of its pipeline and commercial capability in oncology. Zejula (niraparib), a major marketed product, is an oral poly ADP ribose polymerase (PARP) inhibitor that is currently approved in the U.S. and Europe. Clinical trials to assess the use of Zejula in “all-comers” patient populations, as a monotherapy and in combinations, for the significantly larger opportunity of first line maintenance treatment of ovarian cancer are also underway.

    With 23andMe, GSK entered a multi-year collaboration expected to identify novel drug targets, tackle new subsets of disease and enable rapid progression of clinical programs. The four-year collaboration will focus on research and development of innovative new medicines and potential cures, using human genetics as the basis for discovery. The collaboration will combine 23andMe’s large-scale genetic resources and advanced data science skills, with the scientific and medical knowledge and commercialization expertise of GSK. The goal of the collaboration is to gather insights and discover novel drug targets driving disease progression and develop therapies for serious unmet medical needs based on those discoveries.

    With over 5 million customers, 23andMe offers those with an interest in genetics the opportunity to learn more about their personal genetic profile. 23andMe customers can also choose to participate in research and contribute their information to a unique and dynamic database, which is now the world’s largest genetic and phenotypic resource.

    GSK brings extensive drug discovery and development capabilities across a broad range of diseases and modalities, including small molecule, biopharmaceuticals and cell and gene therapies. It will apply its technologies, including access to additional data sources, in-house target validation and genetics expertise, and utilize its manufacturing, commercial operations and scale to support partner activities across research and development.

    R&D alliances
    GSK entered several research collaborations during the year, some of which are highlighted here. A research pact with Fimbrion Therapeutics led to the identification of an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections. The discovery partnership began its joint research efforts in July 2016.

    A three-year extension was made to a tie-up with Neomed-Labs. Under the terms of this renewed agreement, Neomed-Labs will develop immunotools (antigens), immunochemical assays as well as functional assays and undertake the clinical testing for several GSK vaccine projects at the clinical stage.

    Neomed-Labs is a spin-out from GSK’s Clinical Laboratory Services since April 2015 with a three-year original agreement. Following a successful transition from GSK, Neomed-Labs became a fully independent CRO in 2017 and is now collaborating with major global vaccine manufacturers.

    With Syngene International, another global contract research services company, GSK formed a multiyear R&D agreement that will focus on accelerating the discovery of new drug candidates using Syngene’s discovery services platforms. Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas. A team of Syngene scientists will work closely with GSK’s global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world’s most pressing healthcare needs.

    Lastly, GSK entered a technology agreement with LabCorp’s Covance Drug Development business. GSK will use Covance’s Xcellerate Monitoring, Xcellerate Insights, and Xcellerate Clinical Data Hub solutions in a software-as-a-service (SaaS) model. A key component of the technology licensed by GSK is Xcellerate Monitoring, Covance’s implementation of risk-based monitoring, which enables assessment and mitigation of risk at the study, site and patient level. It also allows sponsors to strategically guide site monitoring resources and build quality and efficiency into their clinical trials, from commencement to completion. 
    Related Searches
    • Manufacturing
    • CRO
    • quality
    • collaboration
    Suggested For You
    Syngene Syngene
    Vetio Animal Health Vetio Animal Health
    Pricing Headwinds Pricing Headwinds
    Rawcliffe to Succeed Noble as Adaptimmune CEO Rawcliffe to Succeed Noble as Adaptimmune CEO
    Pfizer, Inc. Pfizer, Inc.
    GSK Opens Two Mfg. Facilities in Singapore GSK Opens Two Mfg. Facilities in Singapore
    GSK Partners with University of California for Genomic Research GSK Partners with University of California for Genomic Research
    Almac Appoints Sheryl Foster VP of Quality Almac Appoints Sheryl Foster VP of Quality
    Thermo Fisher Buys GSK API Site for $100M Thermo Fisher Buys GSK API Site for $100M
    Ebullient Bio CMOs Ebullient Bio CMOs
    GSK Invests $100M to Expand Vaccine Mfg. GSK Invests $100M to Expand Vaccine Mfg.
    GSK, AstraZeneca, CPI to Build Continuous Mfg. Facility GSK, AstraZeneca, CPI to Build Continuous Mfg. Facility
    Celgene Enters AI Drug Discovery Deal with Exscientia Celgene Enters AI Drug Discovery Deal with Exscientia
    PCI Bolsters Supply Chain Leadership PCI Bolsters Supply Chain Leadership
    Gliknik Receives $15M Milestone from Pfizer Gliknik Receives $15M Milestone from Pfizer

    Related Content

    • Syngene

      Syngene

      ...
      Manish, Yadav 07.14.21

    • Vetio Animal Health

      Vetio Animal Health

      ...
      John Kane, CEO 10.24.19

    • Pricing Headwinds

      Pricing Headwinds

      Generic firms see red; CDMOs stay resilient
      S Harachand, Contributing Editor 07.17.19


    • Rawcliffe to Succeed Noble as Adaptimmune CEO

      Rawcliffe to Succeed Noble as Adaptimmune CEO

      Noble will transition to become a Non-Executive Director
      07.16.19

    • Pfizer, Inc.

      Pfizer, Inc.

      ...
      07.15.19

      Loading, Please Wait..
      Trending
      • Regulatory Report: Analytical Procedure Development
      • Pierre Fabre And Lonza Enter Manufacturing Agreement
      • Pfizer, BioNTech Adapt COVID Vax Against Omicron
      • Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
      • Shimadzu Scientific Instruments Extends HQ Campus
      Breaking News
      • Phastar Appoints Chris Schoonmaker as Chief Operations Officer
      • Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK
      • EQT Private Equity Acquires SPT Labtech from Battery Ventures
      • Shimadzu Scientific Instruments Extends HQ Campus
      • Vetter’s Newest Clinical Manufacturing Site Completes First Customer Fills
      View Breaking News >
      CURRENT ISSUE

      June 2022

      • Newsmakers: Darren Shirley
      • Are You Prepared for the 2023 DSCSA Deadline?
      • Rethinking the Changing Role of the CRO
      • 23rd Annual Salary Survey
      • Pharma 4.0 and the Modernizing Power of Digital Technology Transfer
      • CEO Spotlight: David Chang
      • Changes are on the Horizon for Single-use Systems in Pharmaceutical Manufacturing
      • CRO Industry Market Report

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Kensing Acquires Vitae Naturals
      CoQ10 and Royal Jelly Supplementation May Improve High Intensity Exercise
      Shiitake Mushroom Extract Appears Helpful in HPV Infections
      Coatings World

      Latest Breaking News From Coatings World

      Sheboygan Paint Company Adds Rosey Malchow as Customer Experience Manager
      PPG to Announce Second Quarter 2022 Results July 21
      Evonik Unveils Range of Sustainable Liquid Polybutadienes
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Researchers Develop New Apparatus for the Treatment of Cardiovascular Diseases
      NovaXS Unveils New Prototype of Needle-Free Injection Therapy Smart Medical Device
      Meddux Opens New Facility in Boulder, Colorado
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Phastar Appoints Chris Schoonmaker as Chief Operations Officer
      Charles River Labs Opens Plasmid DNA CoE in Cheshire, UK
      EQT Private Equity Acquires SPT Labtech from Battery Ventures
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Highlights from Paris Packaging Week
      Walgreens Boots Alliance Decides Not to Sell Boots and No7 Beauty Company Businesses
      WWP Beauty Unveils New Packaging Collections in Collaboration with Eastman
      Happi

      Latest Breaking News From Happi

      Evonik Holds Groundbreaking Ceremony for Commercial Rhamnolipid Production Facility
      CHT USA Hosts Groundbreaking Ceremony for $20 Million US Headquarters Expansion
      Azelis Expands Global Flavors & Fragrances Platform with Acquisition in India
      Ink World

      Latest Breaking News From Ink World

      Temporary Content Title
      Amcor Lift-Off Initiative Shortlists Start-ups for Seed Funding
      Barentz Highlights Lincoln MFG’s New ISO 9001:2015 Certification
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Sibress launches FADS3D flexo plate measuring device
      Mike Brown appointed VP for Davis-Standard’s Canadian operations
      Constantia Flexibles introduces chemical resistant recycle-ready laminate
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Suominen Launches Hydraspun Reserve
      Richard Knowlson Receives Lifetime Technical Achievement Award
      Skylark Launches Thicker Label Closure Technology in North American
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      Tecomet Appoints Bill Dow as President & CEO
      Medacta, InSilicoTrials Partner on Orthopedic Device Development
      Researchers Develop Microfluidic Sensors to Improve Implant Survival Rates
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Avery Dennison Launches New Dual-Frequency RFID Inlay
      Avery Dennison Highlights New Approach to Apparel with ADX Lab
      trinamiX Face Authentication Protects Users from Fraud Attacks During Mobile Payments

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login